Literature DB >> 8844076

Fragile-X carrier females: evidence for a distinct psychopathological phenotype?

P Franke1, W Maier, M Hautzinger, O Weiffenbach, M Gänsicke, B Iwers, F Poustka, S G Schwab, U Froster.   

Abstract

The present study examined 35 mothers (29 premutation carriers) of children with fragile-X syndrome in measures of intelligence and psychiatric disorders by comparing them with two control groups: a) 30 mothers of children in the general population and b) 17 mothers of non-fra-X retarded children with autism. Premutation carriers had a higher frequency of affective disorders than mothers from the general population. Preliminary data indicate that normally intelligent premutation carriers of the fra-X genetic abnormality have a similar frequency of affective disorders (DSM-III-R criteria [APA, 1987]) than mothers of autistic children. Neither carriers of the premutation nor carriers of the full mutation in the fra-X group obtained a diagnosis of the schizophrenia-spectrum (schizophrenia, schizophreniform disorder, and schizoaffective disorder). Carriers of the fra-X full mutation had considerably lower IQ than carriers of the fra-X premutation. There was a negative correlation between length of CGG repeats and IQ which failed to reach significance in both groups of fra-X carriers. Psychiatric morbidity was not restricted to carriers of the fra-X full mutation only but was also present in normal intelligent premutation carriers. Furthermore the age of onset of psychiatric morbidity in both groups of mothers of fra-X children as well as the group of mothers with autistic children was much earlier than the age when mental retardation had been diagnosed in their children. Increased psychosocial burden of raising a developmentally retarded child and/or feelings of guilt of being a fra-X carrier can therefore not fully explain our findings (three-fold higher frequencies of affective disorders compared to mothers from the general population).

Entities:  

Mesh:

Year:  1996        PMID: 8844076     DOI: 10.1002/(SICI)1096-8628(19960809)64:2<334::AID-AJMG20>3.0.CO;2-F

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  28 in total

Review 1.  Fragile X-associated tremor/ataxia syndrome (FXTAS): pathology and mechanisms.

Authors:  Paul Hagerman
Journal:  Acta Neuropathol       Date:  2013-06-21       Impact factor: 17.088

2.  Emotion recognition and visual-scan paths in Fragile X syndrome.

Authors:  Tracey A Shaw; Melanie A Porter
Journal:  J Autism Dev Disord       Date:  2013-05

3.  Maternal well-being and child behavior in families with fragile X syndrome.

Authors:  Claire T Hauser; Sara T Kover; Leonard Abbeduto
Journal:  Res Dev Disabil       Date:  2014-06-29

Review 4.  Fragile X syndrome. Molecular and clinical insights and treatment issues.

Authors:  R J Hagerman
Journal:  West J Med       Date:  1997-02

5.  Genetic Counseling for Fragile X Syndrome: Recommendations of the National Society of Genetic Counselors.

Authors:  N McIntosh; L W Gane; A McConkie-Rosell; R L Bennett
Journal:  J Genet Couns       Date:  2000-08       Impact factor: 2.537

Review 6.  Early identification of autism in fragile X syndrome: a review.

Authors:  L M McCary; J E Roberts
Journal:  J Intellect Disabil Res       Date:  2012-09-14

Review 7.  Neuropsychiatric symptoms of fragile X syndrome: pathophysiology and pharmacotherapy.

Authors:  John A Tsiouris; W Ted Brown
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

8.  Prevalence and phenotype consequence of FRAXA and FRAXE alleles in a large, ethnically diverse, special education-needs population.

Authors:  D C Crawford; K L Meadows; J L Newman; L F Taft; D L Pettay; L B Gold; S J Hersey; E F Hinkle; M L Stanfield; P Holmgreen; M Yeargin-Allsopp; C Boyle; S L Sherman
Journal:  Am J Hum Genet       Date:  1999-02       Impact factor: 11.025

Review 9.  Fragile X-associated tremor/ataxia syndrome: clinical phenotype, diagnosis, and treatment.

Authors:  Maureen A Leehey
Journal:  J Investig Med       Date:  2009-12       Impact factor: 2.895

Review 10.  Advances in clinical and molecular understanding of the FMR1 premutation and fragile X-associated tremor/ataxia syndrome.

Authors:  Randi Hagerman; Paul Hagerman
Journal:  Lancet Neurol       Date:  2013-08       Impact factor: 44.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.